FitLife Brands Inc

FitLife Brands Inc (FTLF) Stock Analysis

$8.000

-0.176 (-2.20%)At close

Loading chart…
High
8.120
Open
8.120
VWAP
8.04
Volume
6.95K
Mkt Cap
151.74M
Low
8.000
Amount
55.85K
EV/EBITDA, TTM
7.55

FitLife Brands, Inc. is a developer and marketer proprietary nutritional supplements and wellness products for health-conscious consumers. It markets approximately 250 different products primarily online, through domestic and international GNC franchise locations as well as through various retail locations. It offers NDS Nutrition, PMD Sports, SirenLabs, Core Active, Nutrology, and Metis Nutrition (together, NDS Products); iSatori, BioGenetic Laboratories, and Energize (together, the iSatori Products); Dr. Tobias, All Natural Advice, and Maritime Naturals (together, the MRC Products) and MusclePharm. Its NDS brand includes premium weight loss, sports nutrition, and general health products. Its PMD brand includes premium sports nutrition products. Its Nutrology brand included sports nutrition and general wellness products with an emphasis on natural, vegan, and organic ingredients. Its SirenLabs brand includes weight loss and sports nutrition products.

AI analysis of FitLife Brands Inc (FTLF)

Hold

Currently, FitLife Brands Inc (FTLF) is not a strong buy due to its low RSI of 37.37, indicating potential oversold conditions, and a significant year-to-date decline of 49.05%. Although there was a recent revenue growth of 65% year-over-year in Q2 2026, the company's gross margin has declined to 36.01%. The upcoming earnings report on November 16, 2026, could provide more clarity, but the current price of $8.03 and the forward P/E of 6.11 suggest caution as the stock is still underperforming.

Valuation Metrics

The current forward P/E ratio for FitLife Brands Inc (FTLF) is 6.26, compared to its 5-year average forward P/E of 7.67.

Forward P/E

Fair
5Y Average P/E
7.67
Current P/E
6.26
Overvalued
14.10
Undervalued
1.24

Forward EV/EBITDA

Fair
5Y Average EV/EBITDA
5.63
Current EV/EBITDA
7.55
Overvalued
10.22
Undervalued
1.04

Forward P/S

Fair
5Y Average P/S
0.93
Current P/S
0.68
Overvalued
1.78
Undervalued
0.09

Events Timeline

2026-04-01 (ET)

16:30:00

Major Averages Close Broadly Higher as Market Sentiment Improves

12:20:00

Major Averages Broadly Higher as Market Sentiment Improves

07:10:00

Legacy FitLife Reports Q4 Revenue of $25.9M

2025-11-13 (ET)

07:36:28

FitLife Brands Announces Q3 EPS of 9 Cents Compared to 21 Cents Last Year

2025-08-14 (ET)

07:03:17

FitLife Brands reports Q2 EPS 18c vs. 27c last year

News

FTLF FAQ — answered by Alphio AI

FitLife Brands, Inc. is a developer and marketer proprietary nutritional supplements and wellness products for health-conscious consumers. It markets approximately 250 different products primarily online, through domestic and international GNC franchise locations as well as through various retail locations. It offers NDS Nutrition, PMD Sports, SirenLabs, Core Active, Nutrology, and Metis Nutrition (together, NDS Products); iSatori, BioGenetic Laboratories, and Energize (together, the iSatori Products); Dr. Tobias, All Natural Advice, and Maritime Naturals (together, the MRC Products) and MusclePharm. Its NDS brand includes premium weight loss, sports nutrition, and general health products. Its PMD brand includes premium sports nutrition products. Its Nutrology brand included sports nutrition and general wellness products with an emphasis on natural, vegan, and organic ingredients. Its SirenLabs brand includes weight loss and sports nutrition products. It operates in the Consumer Non-Cyclicals sector (MEDICINAL CHEMICALS & BOTANICAL PRODUCTS industry).

Currently, FitLife Brands Inc (FTLF) is not a strong buy due to its low RSI of 37.37, indicating potential oversold conditions, and a significant year-to-date decline of 49.05%. Although there was a recent revenue growth of 65% year-over-year in Q2 2026, the company's gross margin has declined to 36.01%. The upcoming earnings report on November 16, 2026, could provide more clarity, but the current price of $8.03 and the forward P/E of 6.11 suggest caution as the stock is still underperforming.

Community

More ↗

No posts yet

Sign up or log in to join the discussion

Related articles

This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.

Start trading